TG Therapeutics, Inc. (TGTX) Stock Price Today & Analysis
Valuation
Earnings Per Share
Income Statement
Dividend
Solvency
About TG Therapeutics, Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.
FAQ
- Download the Gotrade app from the App Store or Google Play.
- Create an account and complete KYC.
- Make a deposit.
- Search for the code "TGTX", then tap "Trade".
- Tap the "Buy" button.
- Enter the amount you want to buy. You have two options:
- Buy TGTX by number of shares.
- Buy fractional shares in dollars, starting from $1.
- Swipe up to confirm your order—done!
- Compare valuation (e.g., P/E, P/S) against historical averages or competitors.
- Review revenue and earnings growth.
- Check margins and cash flow.
- Evaluate business outlook and the company's position within its industry.





